A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

September 1, 2026

Study Completion Date

September 1, 2026

Conditions
Renal Cell CarcinomaRadiotherapyImmune Checkpoint Inhibitor
Interventions
RADIATION

High-dose Radiotherapy (HDRT)

SBRT was adopted, and radiotherapy plan was made according to the location and size of lesions (total dose 20-70Gy, 5-12Gy every time).

RADIATION

Low-dose Radiotherapy (LDRT)

Radiotherapy plan was made according to the location and size of lesions (total dose 2Gy, 1Gy every time). After completing SBRT, LDRT was performed on as many metastatic sites as possible.

DRUG

Anti-PD-1 monoclonal antibody

At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.

Trial Locations (1)

210000

RECRUITING

Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing

All Listed Sponsors
lead

Jinling Hospital, China

OTHER

NCT06255223 - A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy | Biotech Hunter | Biotech Hunter